News Focus
News Focus
Followers 67
Posts 6013
Boards Moderated 0
Alias Born 09/16/2013

Re: manibiotech post# 725477

Friday, 10/11/2024 11:14:17 AM

Friday, October 11, 2024 11:14:17 AM

Post# of 822365
You are wrong.

First, comparing the bespoke, groundbreaking DCVax platform to a standardized, one-size-fits-all drug is flawed. They are worlds apart and cannot be assessed by the same criteria. It's like trying to wear a glove that just doesn’t fit.

Second, it seems you've overlooked the potential of DCVax to become the universal treatment for all tumor-based cancers.

Third, considering DCVax’s highly personalized and effective nature, wouldn't a franchise model be more advantageous? It could foster much more competition, benefiting patients, the industry, shareholders, and NWBO itself, rather than letting a single pharmaceutical giant monopolize it.

“When bad men combine, the good must associate; else they will fall one by one, an unpitied sacrifice in a contemptible struggle.”

~Edmund Burke

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News